DSM-Firmenich Raises 2026 Sales Outlook After Strong Q3
Direct answer
dsm-firmenich raised its full year 2026 sales growth outlook to around 5% on November 4, 2026, after a stronger third quarter. Sales rose 5% on a like-for-like basis, and adjusted EBITDA reached 482 million euros, slightly above market expectations.
What happened
dsm-firmenich, a Swiss company that makes ingredients, flavors, fragrances, and nutrition products, reported its third quarter 2026 trading update on November 4. The company said growth was led by sales volume, meaning it sold more products, rather than by higher prices alone.
The headline numbers were: Q3 sales of 2,368 million euros, up from 2,238 million euros a year earlier, with like-for-like sales growth of 5%. Q3 adjusted EBITDA of 482 million euros, up from 458 million euros a year earlier. Adjusted EBITDA is a measure of operating profit before interest, tax, depreciation, and amortization, with some one-off items removed. Adjusted EBITDA margin of 20.4% in the quarter. That means about 20.4 euros of adjusted operating profit for every 100 euros of sales. Full year 2026 like-for-like sales growth outlook raised to around 5%, from a previous range of 2% to 4%.
Reuters reported that the 482 million euro result was slightly above the company provided consensus of 478 million euros, and that sales of 2.37 billion euros were slightly above a consensus forecast of 2.36 billion euros. The company’s own trading update, published through GlobeNewswire, confirms the same headline figures.
By business unit in the third quarter: Perfumery and Beauty grew 8% like-for-like, with sales of 1,015 million euros. Fine fragrances and consumer fragrances both performed strongly. Taste, Texture and Health grew 3% like-for-like, with sales of 813 million euros. Europe, Asia, and Latin America performed well, while North America was soft. Health, Nutrition and Care grew 5% like-for-like, with sales of 515 million euros, helped by early life nutrition products.
The company also kept its full year target for an adjusted EBITDA margin of around 20%, and said its 2026 to 2028 action plan remains fully on track. For a related outlook raise, see the Continental outlook post linked above.
Why it matters for beginners
When a company raises its outlook, it is saying it now expects stronger full year results than it expected before. That is usually read as a sign of confidence, but it is still a forecast, not a guaranteed result.
For beginners, three simple ideas help here: Like-for-like growth strips out currency moves and buying or selling businesses, so it gives a cleaner view of underlying demand. A profit margin shows how much profit a company keeps from each unit of sales. A margin near 20% is relatively strong for a large ingredients and nutrition group. One good quarter does not tell the whole story. Investors also watch whether demand stays strong in the final quarter, and whether costs or currency moves eat into profit.
dsm-firmenich products sit behind many everyday items, from food flavors to fragrances, so its results can also give a small window into consumer demand more broadly.
What to watch next
The full year 2026 results, due on February 18, 2027, which will show whether the raised around 5% sales growth outlook was met. Whether Perfumery and Beauty keeps growing at a faster pace than the other two business units. Whether North America demand improves in Taste, Texture and Health and in dietary supplements. Any update on costs, currency effects, and cash conversion, which is how much operating profit turns into cash.
FAQ
What is dsm-firmenich? It is a Swiss company listed in Amsterdam and Switzerland that makes nutrition, health, and beauty ingredients, including flavors and fragrances used by other consumer goods companies.
What does like-for-like mean? It compares sales on a similar basis to last year, removing the effects of currency changes and of businesses bought or sold, so the growth figure reflects underlying trading more clearly.
Why did the company raise its outlook? It cited continued good business momentum, high win rates on customer briefs, and volume-led growth across its portfolio in the third quarter.
Does a raised outlook mean the shares will rise? Not necessarily. Share prices also reflect expectations already in the market, wider market conditions, and future results, so a raised outlook is only one piece of information.
